Emyria (formerly Emerald Clinics) and Zelira Therapeutics have inked a deal to collect data from Emyria patients using Zelira’s cannabinoid-based Zenivol medicine to treat insomnia.
Under the arrangement, de-identified patient data including diagnosis, co-morbidities, concomitant medications, dosage and responses to Zenivol will be assessed using clinical and subjective endpoints including the Insomnia Severity Index (ISI) questionnaire.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.